Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Innate Pharma (IPHYF)

Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Innate Pharma to Host Event on Lacutamab’s Progress and Market Potential Tipranks - Thu Oct 16, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Innate Pharma...

IPHYF : 2.1550 (+13.12%)
Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA) Tipranks - Thu Oct 9, 2025

Goldman Sachs analyst maintained a Hold rating on Innate Pharma today. The company’s shares closed yesterday at $1.95.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

IPHA : 1.7750 (+2.01%)
IPHYF : 2.1550 (+13.12%)
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) Tipranks - Thu Oct 9, 2025

In a report released yesterday, from Goldman Sachs maintained a Hold rating on Innate Pharma SA, with a price target of €2.23. The company’s shares closed last Thursday at $2.00.Elevate Your Investing...

IPHA : 1.7750 (+2.01%)
IPHYF : 2.1550 (+13.12%)

Barchart Exclusives

This Is the Top-Rated Dividend Stock to Buy in February 2026 Barchart - Tue Feb 10, 6:30PM CST
CMCL’s low payout ratio, hedged $3,500‑floor gold pricing, and 56% implied upside from its lone “Strong Buy” target make it an attractive small‑cap dividend grower for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot